Dalton Venture Named to Cyzone's 2026 Most Admired VC Firms in Dual Rankings

道彤投资·September 25, 2026·0·9

Recently, Cyzone released its "**Most Admired Venture Capital Firms 2026**" rankings. **Dalton Venture** was selected for the "**Top 50 Most Admired Early-Stage Investment Firms 2026**" and also made the vertical-sector list "**Top 30 Bio/Medical Technology**."

Honor Roll

Recently, Cyzone released its "Most Admired Venture Capital Firms 2026" rankings. Dalton Venture was named to the "Top 50 Most Admired Early-Stage Investment Firms 2026" and also earned a spot on the vertical-industry list "Top 30 Biotech and MedTech Firms."

After a period of adjustment and restructuring, the venture capital market in 2026 is showing signs of warming. Capital is concentrating further among top-tier firms and technology-driven sectors. How institutions assess value is shifting from market size and growth velocity toward underlying technical moats, industrialization efficiency, and global competitiveness. Meanwhile, LPs' evaluation of GPs has expanded from scale and track record to long-term investment capability and value creation. As the industry enters a phase of competition around professional competence and sustained value, reputation — an asset built from investment performance, professional judgment, and industry credibility — is becoming a critical measure of overall institutional strength.

With this in mind, Cyzone launched its "Most Admired Venture Capital Firms" ranking for the sixth consecutive year. For the first time in the industry, it adopted a "peer review" mechanism, placing decisive evaluative power in the hands of investors working on the front lines. Through this peer lens, the ranking observes firms' professional capabilities and industry standing, surfacing benchmark institutions that combine solid track records, expertise, and brand reputation.

Dalton Venture

Top 50 Most Admired Early-Stage Investment Firms 2026

Dalton Venture

Most Admired Venture Capital Firm 2026

Top 30 Biotech and MedTech

Like-minded and steady in our progress, Dalton Venture has grown into a leading sector-focused investment firm in China. We maintain deep, systematic positions across medical devices and equipment, brain-computer interfaces, biomanufacturing, embodied artificial intelligence, and new materials, with strong investment performance and numerous success stories to show for it. As an early-stage investor, we are gratified to see the value of our persistence: several of our earlier bets on breakthrough technologies have borne fruit, with multiple portfolio companies achieving domestic-first innovations.

Going forward, Dalton Venture will continue to dig deep into our specialized domains, pressing ahead with determination to help more outstanding companies achieve leapfrog growth and create value for the advancement of healthcare.